Commercial Opportunities CHK1- and CHK2-SNPs have been well validated. Genotyping of these SNPs will allow identifying responders and non-responders under therapy with CHK-inhibitors and other anti-cancer drugs. Besides the pre-estimation of the efficacy of pharmacological therapies, dose adjustments of non-pharmacological therapies like irradiation should be possible. Genetic association studies have clearly demonstrated significant effects of CHK1- and CHK2-SNPs upon the outcome in different haematological and solid cancers. For example, excellent correlations with the progression of CLL, bladder, colorectal carcinoma and glioblastoma have been observed. The prognostic value will also be given for other cancer entities. Since the biological function of the CHK1 and CHK2 are well known and characterized, corresponding diagnostic tests will be widely accepted.
email@example.com | TechnologieAllianz e.V.
Flexible and rigid, heavy-metal free organic redox polymer batteries
09.03.2017 | TechnologieAllianz e.V.
Quat primer polymers the universal key to permanent surface functionalization
27.02.2017 | TechnologieAllianz e.V.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
23.03.2017 | Life Sciences
23.03.2017 | Power and Electrical Engineering
23.03.2017 | Earth Sciences